Synapse - Chau Dang

Results (273)

Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)

Meeting Abstract

Wang, R.; Singh, J. C.; Wong, S. T. L.; Lake, D.; Iyengar, N. M.; D'Andrea, G.; Brockway-Marchello, J. P.; Kaba, A.; Traina, T. A.; Robson, M. E.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer

Meeting Abstract

Ferraro, E.; Razavi, P.; Chandarlapaty, S.; Modi, S.; Wen, H. Y.; Brogi, E.; Norton, L.; Robson, M. E.; Dang, C. T.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033), a phase II randomized trial of adjuvant T-DM1 vs. TH in women with stage I HER2 positive breast cancer

Meeting Abstract

Bellon, J. R.; Tayob, N.; Burstein, H. J.; Partridge, A.; Demeo, M. K.; Tralins, J.; Yang, D. D.; Dang, C.; Isakoff, S. J.; Yardley, D.; more...
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast

Meeting Abstract

Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)

Meeting Abstract

Swain, S. M.; Tan, A.; Gianni, L.; Kümmel, S.; Dang, C.; Schneeweiss, A.; O'Shaughnessy, J.; Liu, H.; Aguila, C.; Heeson, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

Journal Article

Ruddy, K. J.; Zheng, Y.; Tayob, N.; Hu, J.; Dang, C. T.; Yardley, D. A.; Isakoff, S. J.; Valero, V. V.; Faggen, M. G.; Mulvey, T. M.; more...
Breast Cancer Research and Treatment (2021)

Fulltext@MSK | Save

Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial

Journal Article

Tolaney, S. M.; Tayob, N.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

NCCN Guidelines® Insights: Breast cancer, version 4.2021: Featured updates to the NCCN Guidelines

Guidelines

Gradishar, W. J.; Moran, M. S.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K. H.; Blair, S. L.; Burstein, H. J.; Dang, C.; Elias, A. D.; more...
Journal of the National Comprehensive Cancer Network (2021)

Fulltext@MSK | Save

Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Meeting Abstract

Dang, C.; Ewer, M. S.; Delaloge, S.; Ferrero, J. M.; Colomer, R.; Merino, L. D.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer

Journal Article

Al-Sadawi, M.; Hussain, Y.; Copeland-Halperin, R. S.; Tobin, J. N.; Moskowitz, C. S.; Dang, C. T.; Liu, J. E.; Steingart, R. M.; Johnson, M. N.; Yu, A. F.
American Journal of Cardiology (2021)

Fulltext@MSK | Save